The trading price of Talis Biomedical Corporation (NASDAQ:TLIS) floating higher at last check on Wednesday, July 21, closing at $12.40, 2.31% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $9.85 and $12.7099. In examining the 52-week price action we see that the stock hit a 52-week high of $33.90 and a 52-week low of $9.43. Over the past month, the stock has gained 23.93% in value.
Talis Biomedical Corporation, whose market valuation is $313.30 million at the time of this writing, is expected to release its quarterly earnings report May 11, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.91 per share this quarter, however they have predicted annual earnings per share of -$3.18 for 2021 and -$1.52 for 2022. It means analysts are expecting annual earnings per share growth of 92.60% this year and 52.20% next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $64.28 million. The company’s revenue is forecast to grow by 487.70% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Talis Biomedical Corporation No upward and no downward comments were posted in the last 7 days.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned TLIS a recommendation rating is 4. Out of them, 1 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Talis Biomedical Corporation (TLIS) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that TLIS’s price is currently 18.39% off the SMA20 and 18.94% off the SMA50. The RSI metric on the 14-day chart is currently showing 65.71, and weekly volatility stands at 11.30%. When measured over the past 30 days, the indicator reaches 7.52%. Talis Biomedical Corporation (NASDAQ:TLIS)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 0.86. With analysts defining $13.00-$17.00 as the low and high price targets, we arrive at a consensus price target of $14.75 for the trailing 12-month period. The current price is about -4.84% off the estimated low and -37.1% off the forecast high, based on this estimate. Investors will be thrilled if TLIS’s share price rises to $14.50, which is the median consensus price. At that level, TLIS’s share price would be -16.94% below current price.
To see how Talis Biomedical Corporation stock has been performing today in comparison to its peers in the industry, here are the numbers: TLIS stock’s performance was 2.31% in the latest trading. Talis Biomedical Corporation has a P/E ratio of 0. Also during today’s trading, the S&P 500 Index has surged 0.58%, while the Dow Jones Industrial also saw a positive session, up 0.66% today.
An evaluation of the daily trading volume of Talis Biomedical Corporation (NASDAQ:TLIS) indicates that the 3-month average is 240.97K. However, this figure has increased over the past 10 days to an average of 0.54 million.
Currently, records show that 23.48 million of the company’s shares remain outstanding. The insiders hold 1.20% of outstanding shares, whereas institutions hold 82.00%. The stats also highlight that short interest as of May 27, 2021, stood at 2.05 million shares, resulting in a short ratio of 20.85 at that time. From this, we can conclude that short interest is 7.99% of the company’s total outstanding shares. It is noteworthy that short shares in May were down slightly from the previous month’s figure, which was 2.05 million. However, since the stock’s price has seen -56.40% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.